Biosig Technologies, Common Stock Beta
| BSGM Stock | USD 1.10 0.32 22.54% |
BioSig Technologies, Common fundamentals help investors to digest information that contributes to BioSig Technologies,'s financial success or failures. It also enables traders to predict the movement of BioSig OTC Stock. The fundamental analysis module provides a way to measure BioSig Technologies,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioSig Technologies, otc stock.
BioSig |
BioSig Technologies, Common OTC Stock Beta Analysis
BioSig Technologies,'s Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current BioSig Technologies, Beta | 0.84 |
Most of BioSig Technologies,'s fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioSig Technologies, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, BioSig Technologies, Common has a Beta of 0.839. This is 2.44% lower than that of the Health Care Equipment & Supplies sector and 19.33% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
BioSig Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioSig Technologies,'s direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of BioSig Technologies, could also be used in its relative valuation, which is a method of valuing BioSig Technologies, by comparing valuation metrics of similar companies.BioSig Technologies, is currently under evaluation in beta category among its peers.
As returns on the market increase, BioSig Technologies,'s returns are expected to increase less than the market. However, during the bear market, the loss of holding BioSig Technologies, is expected to be smaller as well.
BioSig Fundamentals
| Return On Equity | -59.77 | ||||
| Return On Asset | -4.48 | ||||
| Operating Margin | (227.43) % | ||||
| Current Valuation | 6.43 M | ||||
| Shares Outstanding | 14.12 M | ||||
| Shares Owned By Insiders | 17.59 % | ||||
| Shares Owned By Institutions | 3.04 % | ||||
| Number Of Shares Shorted | 461.7 K | ||||
| Price To Earning | (3.73) X | ||||
| Price To Book | 36.58 X | ||||
| Price To Sales | 90.04 X | ||||
| Revenue | 18 K | ||||
| Gross Profit | 242 K | ||||
| EBITDA | (28.15 M) | ||||
| Net Income | (28.69 M) | ||||
| Cash And Equivalents | 887 K | ||||
| Cash Per Share | 0.02 X | ||||
| Total Debt | 452 K | ||||
| Debt To Equity | 0.45 % | ||||
| Current Ratio | 1.22 X | ||||
| Book Value Per Share | (0.39) X | ||||
| Cash Flow From Operations | (17.31 M) | ||||
| Short Ratio | 0.95 X | ||||
| Earnings Per Share | (0.86) X | ||||
| Target Price | 6.0 | ||||
| Beta | 0.84 | ||||
| Market Capitalization | 6.64 M | ||||
| Total Asset | 1.8 M | ||||
| Retained Earnings | (245.01 M) | ||||
| Working Capital | (4.05 M) | ||||
| Current Asset | 984.54 K | ||||
| Current Liabilities | 2.47 M | ||||
| Net Asset | 1.8 M |
About BioSig Technologies, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioSig Technologies, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioSig Technologies, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioSig Technologies, Common based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in BioSig OTC Stock
BioSig Technologies, financial ratios help investors to determine whether BioSig OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioSig with respect to the benefits of owning BioSig Technologies, security.